Localized prostate cancer shows great clinical, genetic and environmental heterogeneity;
however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA …

Organismal aging exhibits wide-ranging hallmarks in divergent cell types across tissues,
organs, and systems. The advancement of single-cell technologies and generation of rich …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

The identification of prostate stem/progenitor cells and characterization of the prostate
epithelial cell lineage hierarchy are critical for understanding prostate cancer initiation. Here …

Lineage transitions are a central feature of prostate development, tumourigenesis and
treatment resistance. While epigenetic changes are well known to drive prostate lineage …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Simple Summary Metastatic progression represents a major clinical challenge and remains
the leading cause of death in cancer patients. Identification of suitable therapeutic targets …

Understanding the cellular constituents of the prostate is essential for identifying the cell of
origin for prostate adenocarcinoma. Here, we describe a comprehensive single-cell atlas of …

Benign prostatic hyperplasia (BPH) is a progressive expansion of peri‐urethral prostate
tissue common in aging men. Patients with enlarged prostates are treated with 5‐alpha …

Due to late onset hypogonadism (LOH), there is an increased usage of testosterone
replacement therapy (TRT) in the aging male population. Since prostate is a target organ for …